Table 1 Clinicopathological parameters of the examined cohorts
Clinicopathological parameter | Cohort 1 (n = 101) | Cohort 2 (n = 46) | P value | |
|---|---|---|---|---|
Menstrual status | 0.343 | |||
postmenopause | 48 (47.5%) | 18 (39.1%) | ||
premenopause | 53 (52.5%) | 28 (60.9%) | ||
Age (years) a | 49.762 ± 14.265 | 54.391 ± 11.174 | 0.054 | |
Tumor location | 0.317 | |||
U | 20 (19.8%) | 5 (10.9%) | ||
M | 41 (40.6%) | 18 (39.1%) | ||
L | 40 (39.6%) | 23 (50.0%) | ||
CEA b | 1.955 (1.110, 3.915) | 2.120 (1.110, 3.930) | 0.587 | |
CA125 b | 16.400 (10.300, 57.200) | 16.050 (9.900, 54.300) | 0.902 | |
CA125/CEA b | 8.389 (4.375, 23.694) | 6.503 (2.899, 22.187) | 0.939 | |
CA724 b | 3.640 (1.480, 7.782) | 3.620 (1.580, 7.560) | 0.923 | |
CA19-9 b | 12.830 (4.900, 70.752) | 12.830 (7.130, 53.810) | 0.770 | |
Group | 0.862 | |||
Without SOM | 63 (62.4%) | 28 (60.9%) | ||
With SOM | 38 (37.6%) | 18 (39.1%) | ||